Harbour Biomed closed a year‑end collaboration with Bristol Myers Squibb to develop multispecific antibodies, receiving roughly $90 million up front with potential milestones topping $1 billion. The deal underscores continued big‑pharma interest in multispecific platforms and adds strategic funding and validation to Harbour’s antibody discovery engine. Harbour’s partnership calendar this year signals a broader trend of Western pharmas tapping smaller, Asia‑origin biotechs for novel biologics capabilities.